Abbott Laboratories (ABT) Rated as Buy: Strong Upside Potential Ahead

Abbott Laboratories (NYSE: ABT) has received an upgraded rating from Ed Ridley-Day of Rothschild & Co, moving to a 'Buy' from a previous stance as of October 2, 2026. This recommendation comes as investors take note of Abbott's current price trajectory, coupled with an optimistic price target of $127, suggesting a significant upside from its recent trading levels.

Recent Price Action

Trading at $96.71, Abbott Laboratories' stock currently reflects a challenging environment, evidenced by a recently observed decline of approximately 0.1% with a change of -0.085. The stock is notably trading well below its 52-week high of $117.40, indicating a substantial setback of about 17.69%. However, the lower end of its trading range shows resilience, with a 52-week low recorded at $10.42. The trading volume of 3.11 million shares is markedly lower than its average of 10.88 million, hinting at reduced market activity and potential investor caution. The beta of 0.586 further suggests that Abbott's stock is less volatile than the overall market, typically appealing to more risk-averse investors.

Historical Performance

In terms of performance metrics, Abbott Laboratories has experienced a complex trajectory over recent months. Over the last 30 days, the stock has depreciated by 4.4%, with a quarterly decline of 5.76%. Notably, this performance contrasts with a more favorable annual return of 6.35%. The stock has exhibited a weekly volatility of 1.51% and a monthly volatility of 1.62%, indicating that although Abbott is less volatile than many peers, fluctuations are still present. The average trading volumes over ten and thirty days stand at 8.17 million and 9.52 million, respectively, painting a picture of a stock that, while under pressure, remains on the radar of investors.

Earnings Analysis

Abbott Laboratories has shown strong earnings quality as per its latest performance. During its most recent earnings report on July 16, 2026, the company registered an actual EPS of $1.31, surpassing analysts’ expectations of an estimated $1.28, resulting in a positive surprise factor of approximately 2.34%. This follows a previous EPS report from April 16, 2026, where the company delivered an actual earnings of $1.15 against an estimated $1.14 — indicating a consistent pattern of meeting or exceeding expectations. Such performance signals stability and an ability to navigate challenging market conditions.

Consensus Ratings

The sentiment among analysts surrounding Abbott remains robust, with the company receiving twelve buy ratings and no holds or sells, reflecting a unanimous consensus on its potential. Rothschild & Co's recent upgrade aligns with an average price target of $121.67. The targets range from a conservative $112 to an optimistic $135, suggesting a considerable outlook for growth despite the current market challenges.

Stock Grading or Fundamental View

Abbott Laboratories has achieved a Stocks Telegraph (ST) Score of 47, which offers insights into its fundamental health and investment viability. While this score indicates room for improvement, it suggests that Abbott holds a solid position within the industry, supported by a range of favorable financial metrics and a proactive approach to innovation and product development.

Conclusion

For investors considering their options, Abbott Laboratories represents an intriguing opportunity, particularly for those with a long-term growth mindset. While the recent trajectory suggests some volatility and short-term challenges, the strong upgrades from analysts and an encouraging earnings track record indicate potential for significant returns as market conditions improve. Nonetheless, investors should remain cognizant of possible risks, including market fluctuations and industry competition, but with a promising upside hinted at by its current rating and price targets, Abbott warrants close attention in any diversified investment strategy.